8-144082779-G-T
Variant summary
Our verdict is Likely benign. Variant got -2 ACMG points: 2P and 4B. PM2BP4_Strong
The NM_003801.4(GPAA1):c.49G>T(p.Val17Leu) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000389 in 1,466,884 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 13/20 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★★).
Frequency
Consequence
NM_003801.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_benign. Variant got -2 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
GPAA1 | NM_003801.4 | c.49G>T | p.Val17Leu | missense_variant | 1/12 | ENST00000355091.9 | NP_003792.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
GPAA1 | ENST00000355091.9 | c.49G>T | p.Val17Leu | missense_variant | 1/12 | 1 | NM_003801.4 | ENSP00000347206 | P4 |
Frequencies
GnomAD3 genomes AF: 0.000237 AC: 36AN: 152144Hom.: 0 Cov.: 33
GnomAD3 exomes AF: 0.0000265 AC: 2AN: 75542Hom.: 0 AF XY: 0.0000231 AC XY: 1AN XY: 43336
GnomAD4 exome AF: 0.0000160 AC: 21AN: 1314632Hom.: 0 Cov.: 31 AF XY: 0.0000170 AC XY: 11AN XY: 647132
GnomAD4 genome AF: 0.000236 AC: 36AN: 152252Hom.: 0 Cov.: 33 AF XY: 0.000188 AC XY: 14AN XY: 74442
ClinVar
Submissions by phenotype
Inborn genetic diseases Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Jun 15, 2021 | The c.49G>T (p.V17L) alteration is located in exon 1 (coding exon 1) of the GPAA1 gene. This alteration results from a G to T substitution at nucleotide position 49, causing the valine (V) at amino acid position 17 to be replaced by a leucine (L). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
not provided Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jul 06, 2022 | This sequence change replaces valine, which is neutral and non-polar, with leucine, which is neutral and non-polar, at codon 17 of the GPAA1 protein (p.Val17Leu). The frequency data for this variant in the population databases is considered unreliable, as metrics indicate poor data quality at this position in the gnomAD database. This variant has not been reported in the literature in individuals affected with GPAA1-related conditions. ClinVar contains an entry for this variant (Variation ID: 1375678). Algorithms developed to predict the effect of missense changes on protein structure and function output the following: SIFT: "Tolerated"; PolyPhen-2: "Benign"; Align-GVGD: "Class C0". The leucine amino acid residue is found in multiple mammalian species, which suggests that this missense change does not adversely affect protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at